Process for producing composite injection formulation for treating esophagus cancer

Abstract

The invention provides a method for preparing a compounded injection preparation for treating esophagus cancer. The method comprises the following steps: taking raw plasma out from a blood bank according to different blood groups; extracting low density lipoproteins from the raw plasma through the centrifugation and density adjustment treatment; preparing and obtaining targeting drug vectors by the purification of the low density lipoproteins; then compounding the targeting drug vectors with aclacinomycin targeting drugs which are used for treating cancer; and injecting the compounded low density lipoprotein-aclacinomycin drugs into a patient matched with the blood group of drug raw plasma to achieve the purpose of esophagus cancer treatment. The clinical practices prove that the low density lipoprotein-aclacinomycin compounded injection preparation achieves satisfactory curative effects in clinical esophagus cancer treatment without obvious toxic and side effects of chemotherapy, is used for treating 252 esophagus cancer sufferers with the effective rate reaching 100% and the survival rate above 96%, and has good values of popularization and utilization.

Description

technical field [0001] The invention relates to a preparation for treating esophageal cancer, in particular to a preparation method of a compound intravenous injection preparation for treating esophageal cancer and a preparation method thereof. Background technique [0002] With the aggravation of environmental pollution and changes in people's diet structure, the incidence and mortality of esophageal cancer are increasing year by year, seriously endangering the health of the people. In the treatment plan of esophageal cancer, chemotherapy is still the main means in its comprehensive treatment measures. At present, the common deficiency of the chemotherapeutic drugs used in the chemotherapy of various tumors is that the anti-tumor chemotherapeutic drugs lack selectivity. While killing cancer cells, they also damage healthy cells, reduce the immune function of the human body, and cause many toxic effects. Side effects affect the clinical application of chemotherapy drugs. In...

AI Technical Summary

Problems solved by technology

At present, the common deficiency of the chemotherapeutic drugs used in the chemotherapy of various tumors is that the anti-tumor chemotherapeutic drugs lack selectivity. While killing cancer cells, they also damage healthy cells, reduce the immune function of the human body, and cause many toxic effects. Side effects affect the clinical application of chemotherapy drugs. In order to improve the efficacy of anti-tumor drugs and reduce the damage and toxicity to normal cells, the medical community has tried many times to use antibodies, liposomes, hormones and other macromolecules as tumor chemotherapy drugs. Carriers, in order to increase the targeting of drugs, that is, "targeted therapy"

However, a major problem in the actual clinical application process is that the reticuloendothelial system of the liver and spleen removes these complexes in the blood as foreign harmful substances and quickly removes them from the blood stream, thereby reducing the impact of the drug-macromolecular complex on the bloodstream. The time of action of tumor cells affects the therapeutic effect of drugs